净利大降70%，总裁闪辞，华润开始“抢救”龙头

Core Viewpoint - The article discusses the challenges and strategic shifts faced by Boya Biological, a blood product platform under China Resources, as it navigates a downturn in the blood product industry while seeking to establish itself as a leader in the sector. Group 1: Management Changes - Boya Biological has experienced significant management changes, including the resignation of President Ren Hui after less than a year, reflecting the company's response to industry pressures and the need for a leadership capable of navigating through challenging times [2][19]. - The management transitions at both Tian Tan Biological and Boya Biological are seen as attempts to reconstruct growth logic amid a collective industry downturn [2][19]. Group 2: Business Development Phases - Boya Biological's development can be divided into three phases: initial stabilization post-acquisition by China Resources, a phase of asset divestiture to refocus on core blood products, and a current phase of aggressive expansion through acquisitions [3][21][24]. - The company has been actively divesting non-core assets from 2023 to 2025, resulting in a significant drop in net profit but increasing the proportion of revenue from blood products, which is viewed positively by the market [6][21]. Group 3: Acquisition Strategy - In July 2024, Boya Biological acquired 100% of Green Cross Hong Kong for 1.82 billion yuan, gaining access to several key blood product varieties and expanding its plasma collection network [9][24]. - The acquisition is part of Boya's strategy to enhance its market position and scale in the blood product industry, which is critical for competing with industry leaders [7][22]. Group 4: Financial Performance - Boya Biological's financial outlook for 2025 indicates a projected revenue increase of 10%-25% to between 1.908 billion and 2.169 billion yuan, but a significant decline in net profit by 65.62%-73.55% is expected, highlighting the "growth without profit" dilemma [14][29]. - The company faces challenges from industry-wide pressures such as centralized procurement, DRG/DIP reforms, and increased competition, which have led to a decrease in gross margins for blood products [17][31]. Group 5: Research and Development - Boya Biological is expanding its product pipeline, with new products like a high-concentration immunoglobulin approved for market release, which is expected to enhance its product offerings and improve plasma utilization [14][30]. - The company is also investing in R&D, with a reported expenditure of 44.72 million yuan in the first half of 2025, representing 4.44% of its revenue, to support the development of new therapies and expand its product range [16][31].